Equities research analysts forecast that Geron Co. (NASDAQ:GERN) will report earnings of ($0.05) per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Geron’s earnings, with estimates ranging from ($0.06) to ($0.05). Geron also reported earnings of ($0.05) per share in the same quarter last year. The business is scheduled to announce its next earnings results on Wednesday, August 2nd.

According to Zacks, analysts expect that Geron will report full year earnings of ($0.09) per share for the current fiscal year, with EPS estimates ranging from ($0.23) to $0.15. For the next financial year, analysts forecast that the business will report earnings of $0.02 per share, with EPS estimates ranging from ($0.19) to $0.23. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Geron.

Geron (NASDAQ:GERN) last posted its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.05). The business had revenue of $0.54 million for the quarter, compared to analyst estimates of $0.27 million. Geron had a negative net margin of 469.51% and a negative return on equity of 21.96%. Geron’s revenue was down 28.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.06) EPS.

A number of equities research analysts have recently issued reports on GERN shares. FBR & Co reaffirmed a “buy” rating on shares of Geron in a report on Thursday, April 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Geron in a report on Thursday, March 2nd. Zacks Investment Research cut shares of Geron from a “buy” rating to a “hold” rating in a report on Tuesday, May 2nd. Stifel Nicolaus reaffirmed a “hold” rating and issued a $2.50 target price on shares of Geron in a report on Wednesday, April 12th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $5.00 target price on shares of Geron in a report on Wednesday, April 12th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Geron has a consensus rating of “Hold” and a consensus target price of $3.88.

WARNING: “Geron Co. (GERN) Expected to Post Earnings of -$0.05 Per Share” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/05/25/geron-co-gern-expected-to-post-earnings-of-0-05-per-share.html.

Several large investors have recently modified their holdings of the stock. Tudor Investment Corp ET AL boosted its position in Geron by 12.1% in the first quarter. Tudor Investment Corp ET AL now owns 52,369 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 5,669 shares in the last quarter. Two Sigma Securities LLC boosted its position in Geron by 309.4% in the third quarter. Two Sigma Securities LLC now owns 52,939 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 40,008 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in Geron by 31.0% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 57,056 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 13,500 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in Geron during the first quarter valued at $143,000. Finally, Bank of America Corp DE boosted its position in Geron by 26.5% in the first quarter. Bank of America Corp DE now owns 65,403 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 13,698 shares in the last quarter. 37.66% of the stock is currently owned by institutional investors.

Geron (NASDAQ:GERN) opened at 3.07 on Thursday. Geron has a 1-year low of $1.81 and a 1-year high of $3.15. The firm has a 50-day moving average of $2.61 and a 200-day moving average of $2.25. The stock’s market cap is $488.67 million.

Geron Company Profile

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

12 Month Chart for NASDAQ:GERN

Get a free copy of the Zacks research report on Geron (GERN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Geron Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Co. and related companies with MarketBeat.com's FREE daily email newsletter.